Ignite Creation Date:
2025-12-25 @ 12:18 AM
Ignite Modification Date:
2026-01-25 @ 12:52 AM
Study NCT ID:
NCT00649558
Status:
COMPLETED
Last Update Posted:
2024-04-24
First Post:
2008-03-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077205', 'term': 'Pioglitazone'}], 'ancestors': [{'id': 'D045162', 'term': 'Thiazolidinediones'}, {'id': 'D013844', 'term': 'Thiazoles'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 36}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2003-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-04', 'completionDateStruct': {'date': '2003-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-04-22', 'studyFirstSubmitDate': '2008-03-30', 'studyFirstSubmitQcDate': '2008-03-31', 'lastUpdatePostDateStruct': {'date': '2024-04-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2008-04-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2003-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Bioequivalence', 'timeFrame': 'within 30 days'}]}, 'conditionsModule': {'conditions': ['Healthy']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://www.mpibiostudies.com', 'label': 'Mylan Pharmaceuticals Inc. - Clinical Trial Results'}, {'url': 'http://dailymed.nlm.nih.gov/dailymed/about.cfm', 'label': 'Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use'}, {'url': 'http://www.fda.gov/opacom/7alerts.html', 'label': 'Recalls, Market Withdrawals and Safety Alerts'}]}, 'descriptionModule': {'briefSummary': 'The objective of this study was to investigate the bioequivalence of Mylan pioglitazone HCl 45 mg tablets to Takeda Actos® 45 mg tablets following a single, oral 45 mg (1 x 45 mg) dose administration under fasting conditions.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Age: 18 years and older.\n2. Sex: Male and non-pregnant, non-lactating female\n\n 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration. If dosing is scheduled on Sunday or Monday, the HCG pregnancy test should be given within 48 hours prior to dosing of each study period. An additional serum (Beta HCG) pregnancy test will be performed upon completion of the study.\n 2. Women of childbearing potential must practice abstinence or be using an acceptable form of contraception throughout the duration of the study. No hormonal contraceptives or hormonal replacement therapy are permitted in this study. Acceptable forms of contraception include the following:\n\n 1. intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or\n 2. barrier methods containing or used in conjunction with a spermicidal agent, or\n 3. surgical sterility (tubal ligation, oophorectomy or hysterectomy) or postmenopausal accompanied with a documented postmenopausal course of at least one year.\n 3. During the course of the study, from study screen until study exit including the washout period, women of childbearing potential must use a spermicide containing barrier method of contraception in addition to their current contraceptive device. This advice should be documented in the informed consent form.\n3. Weight: At least 60 kg (132 lbs) for men and 48 kg (106 lbs) for women and within 15% of Ideal Body Weight (IBW), as referenced by the Table of ""Desirable Weights of Adults"" Metropolitan Life Insurance Company, 1999 (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).\n4. All subjects should be judged normal and healthy during a pre-study medical evaluation (physical examination, laboratory evaluation, 12-lead ECG, hepatitis B and hepatitis C tests, HIV test, and urine drug screen including amphetamine, barbiturates, benzodiazepine, cannabinoid, cocaine, opiates, phencyclidine, and methadone) performed within 14 days of the initial dose of study medication.\n\nExclusion Criteria:\n\n1. Institutionalized subjects will not be used.\n2. Social Habits:\n\n 1. Use of any tobacco products.\n 2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within the 48 hours prior to the initial dose of study medication.\n 3. Ingestion of any vitamins within the 48 hours prior to the initial dose of the study medication.\n 4. Any recent, significant change in dietary or exercise habits.\n3. Medications:\n\n 1. Use of any medication within the 14 days prior to the initial dose of study medication.\n 2. Use of any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication.\n4. Diseases:\n\n 1. History of any significant chronic disease and/or hepatitis.\n 2. History of drug and/or alcohol abuse.\n 3. Acute illness at the time of either the pre-study medical evaluation or dosing.\n5. Abnormal and clinically significant laboratory test results:\n\n 1. Clinically significant deviation from the Guide to Clinically Relevant Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).\n 2. Abnormal and clinically relevant ECG tracing.\n6. Donation or loss of a significant volume of blood or plasma (\\> 450 mL) within 28 days prior to the initial dose of study medication.\n7. Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.\n8. Allergy or hypersensitivity to pioglitazone HCl, any of the inactive ingredients, or other related products.\n9. History of difficulties in swallowing, or any gastrointestinal disease which could affect the drug absorption.\n10. Consumption of grapefruit or grapefruit containing products within 7 days of drug administration.'}, 'identificationModule': {'nctId': 'NCT00649558', 'briefTitle': 'Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg', 'organization': {'class': 'INDUSTRY', 'fullName': 'Viatris Inc.'}, 'officialTitle': 'Single-Dose Fasting In Vivo Bioequivalence Study of Pioglitazone HCl Tablets (45 mg; Mylan) and Actos® Tablets (45 mg; Takeda) in Healthy Volunteers', 'orgStudyIdInfo': {'id': 'PIOG-02139'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': '1', 'description': 'Pioglitazone HCl Tablets 45 mg', 'interventionNames': ['Drug: Pioglitazone HCl Tablets 45 mg']}, {'type': 'ACTIVE_COMPARATOR', 'label': '2', 'description': 'Actos® Tablets 45 mg', 'interventionNames': ['Drug: Actos® Tablets 45 mg']}], 'interventions': [{'name': 'Pioglitazone HCl Tablets 45 mg', 'type': 'DRUG', 'description': '45mg, single dose fasting', 'armGroupLabels': ['1']}, {'name': 'Actos® Tablets 45 mg', 'type': 'DRUG', 'description': '45mg, single dose fasting', 'armGroupLabels': ['2']}]}, 'contactsLocationsModule': {'locations': [{'zip': '58104', 'city': 'Fargo', 'state': 'North Dakota', 'country': 'United States', 'facility': 'PRACS Institute, Ltd.', 'geoPoint': {'lat': 46.87719, 'lon': -96.7898}}], 'overallOfficials': [{'name': 'James D Carlson, Pharm. D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'PRACS Institute Ltd.'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Mylan Pharmaceuticals Inc', 'class': 'INDUSTRY'}, 'responsibleParty': {'oldNameTitle': 'Will Sullvan, Global Head of Product Risk and Safety Management', 'oldOrganization': 'Mylan Inc.'}}}}